Evaluation of Intercorrelations Between Lipid Profiles in Patients with Type 2 Diabetes Mellitus in the Al-Muthanna Governorate of Iraq

Ahmed A. N. Alfahad

doi:10.51699/cajmns.v7i3.3238

Authors

Ahmed A. N. Alfahad Open Educational College – Muthanna Study Center

DOI:

https://doi.org/10.51699/cajmns.v7i3.3238

Keywords:

Diabetes, TG, Cholesterol, LDL, HDL

Abstract

The well-known metabolic condition known as type 2 diabetes mellitus is distinguished by its chronic nature and compromised lipid metabolism. Recognising and treating it is crucial due to its high prevalence, which affects about one in ten people worldwide. The object of this search was to investigate the relevance between diabetes type 2 and lipid profiles in the people of Al-Muthanna, Iraq. Additionally, we wanted to compare blood lipid levels in patients and healthy people. In our study, patients with type 2 diabetes and healthy people display statistically significant divergence (p < 0.001). With (p < 0.001) values, the parameters of cholesterol, treglycerides (TG), the high-densety lipoprotein (HDL) and low-density lipoprotein (LDL), cholesterol displayed varying degrees of significance. In a number of important areas, our study revealed significant differences between the healthy control group and those with type 2 diabetes. These variations, specifically the elevated standard of (LDL) cholesterol, triglycerides, and cholesterol in diabetes type 2 patients, point to a possible impact of these markers on the severity of the illness.

References

A. Rahman and S. Islam, “The complications of long time treatment of insulin therapy in type-2 diabetes patients: A review,” Mol. Mech. Res., vol. 2, pp. 3–4, 2024.

A. M. Tambascia, M. Gomes, and S. A. Dib, “Tratamento e acompanhamento do diabetes mellitus,” in Diretrizes da Sociedade Brasileira de Diabetes, Rio de Janeiro, Brazil: Diagraphic Editora, 2007, pp. 8–163.

A. A. Yameny, “Diabetes mellitus overview 2024,” J. Biosci. Appl. Res., vol. 10, no. 3, pp. 641–645, 2024, doi: 10.21608/jbaar.2024.382794.

W. H. Almalki and M. S. Khan, “Burden of diabetes mellitus on health and economy of the Arab world: Current situation and perspectives,” J. Public Health (Berl.), pp. 1–20, 2025, doi: 10.1007/s10389-025-02448-7.

M. Di Marco et al., “Cardiovascular risk and renal injury profile in subjects with type 2 diabetes and non-albuminuric diabetic kidney disease,” Cardiovasc. Diabetol., vol. 22, no. 1, p. 344, 2023, doi: 10.1186/s12933-023-02065-2.

J. Ballena-Caicedo et al., “Global prevalence of dyslipidemias in the general adult population: A systematic review and meta-analysis,” J. Health Popul. Nutr., vol. 44, no. 1, p. 308, 2025, doi: 10.1186/s41043-025-01054-3.

A. W. Khan and K. A. Jandeleit-Dahm, “Atherosclerosis in diabetes mellitus: Novel mechanisms and mechanism-based therapeutic approaches,” Nat. Rev. Cardiol., 2025, doi: 10.1038/s41569-024-01115-w.

S. C. Pal and N. Méndez-Sánchez, “Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis,” World J. Gastroenterol., vol. 29, no. 25, p. 3999, 2023, doi: 10.3748/wjg.v29.i25.3999.

S. A. A. Latheef, B. S. Reddy, and B. M. Reddy, “An exploratory study of the non-communicable disease risk factors in an endogamous caste population of Reddys from Tirupati, India,” J. Anthropol. Surv. India, vol. 17, no. 2, pp. 5–11, 2023.

N. Mittman et al., “Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients,” Kidney Int., vol. 78, pp. S41–S45, 2010.

Z. Kashi et al., “The role of metformin response in lipid metabolism in patients with recent-onset type 2 diabetes: HbA1c level as a criterion for designating patients as responders or nonresponders to metformin,” PLoS One, vol. 11, no. 3, 2016.

S. John and R. E. Schmieder, “Impaired endothelial function in arterial hypertension and hypercholesterolemia,” J. Hypertens., vol. 18, pp. 363–374, 2000.

G. Assmann, “The prospective cardiovascular Münster study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease,” Univ. Münster, Germany, 2004.

D. S. Prince, N. Kamalakkannan, and V. P. Menon, “Antidiabetic and antihyperlipidemic effect of alcoholic Syzygium cumini seeds in alloxan-induced diabetic albino rats,” J. Ethnopharmacol., vol. 91, pp. 209–213, 2004.

S. Maxwell et al., “Comparison of antioxidants in lipoprotein fraction from insulin-dependent diabetes and healthy controls,” Atherosclerosis, vol. 129, no. 1, pp. 89–96, 2011.

N. G. L. and N. S. L., “Risk of myocardial infarction attributable to elevated levels of total cholesterol among hypertensives,” Am. J. Hypertens., vol. 18, pp. 759–766, 2005.

T. Hirano, “Pathophysiology of diabetic dyslipidemia,” J. Atheroscler. Thromb., vol. 25, no. 9, pp. 771–782, 2018, doi: 10.5551/jat.RV17023.

J. D. Schofield et al., “Diabetes dyslipidemia,” Diabetes Ther., vol. 7, no. 2, pp. 203–219, 2016, doi: 10.1007/s13300-016-0167-x.

A. R. Tall, “CETP inhibitors to increase HDL cholesterol levels,” N. Engl. J. Med., vol. 356, no. 13, pp. 1364–1366, 2007, doi: 10.1056/NEJMe078029.

H. Shimano and R. Sato, “SREBP-regulated lipid metabolism: Convergent physiology—divergent pathophysiology,” Nat. Rev. Endocrinol., vol. 13, no. 12, pp. 710–730, 2017, doi: 10.1038/nrendo.2017.91.